IntraBio’s team translates research into potential treatments that aim to significantly improve the lives of patients, their caregivers, and families.
IntraBio’s investigational lead drug, IB1001, is an orally administered, modified amino acid (N-Acetyl-L-Leucine) with the potential to provide a meaningful advance in the treatment paradigm for rare neurodegenerative diseases.
IB1001 has been shown to enter enzyme-controlled pathways to correct metabolic dysfunction, improve lysosomal function, and enhance mitochondrial function/ATP production. IB1001 is an investigational product and has not been approved by the US FDA or any regulatory agency for the treatment of any indications.
Details of IntraBio’s clinical studies are published in the world’s leading medical journals.
